As albumin is a strong prognostic marker in ESRD patients on HD therapy, it needs to be as an outcome measure in clinical trials evaluating the effect of periodontal treatment on impairing quality of life of CKD patients. The gene discussed is ALB; the disease is chronic kidney disease.